Table 1.

Eight FDA-approved therapeutic agents in acute myeloid leukaemia (AML).

Therapeutic Agents	Indications
FLT3 inhibitors
1. Midostaurin	Newly diagnosed FLT3-mutated AML
2. Gilteritinib	Relapsed/refractory FLT3-mutated AML
IDH inhibitors
3. Ivosidenib	Relapsed/refractory IDH1-mutated AML
4. Enasidenib	Newly diagnosed or relapsed/refractory IDH2-mutated AML
BCL2 inhibitor
5. Venetoclax + hypomethylating agents or LoDAC	Newly diagnosed AML aged ≥ 75
Hedgehog pathway inhibitor
6. Glasdegib + LoDAC	Newly diagnosed AML aged ≥ 75
Liposomal combination of daunorubicin and cytarabine
7. CPX-351	Newly diagnosed AML-MRC and t-AML
Antibody-chemotherapy adjunct
8. Gemtuzumab ozogamicin	Newly diagnosed and relapsed/refractory CD33-positive AML

MRC: MDS-related changes; t-AML: transformed AML; LoDAC: low-dose cytarabine.